Clinical Trials Logo

Antibiotic Resistant Infection clinical trials

View clinical trials related to Antibiotic Resistant Infection.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05442736 Completed - Clinical trials for Antibiotic Resistant Infection

Modified Surface of PLGA Nanoparticles in Smart Hydrogel

Start date: April 2, 2022
Phase: Early Phase 1
Study type: Interventional

Nanoparticles containing antibiotic were prepared and incorporated in in situ gel to treat recurrent endodontic infections

NCT ID: NCT05391035 Completed - Clinical trials for Antibiotic Resistant Infection

The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.

Guardian
Start date: October 1, 2019
Phase:
Study type: Observational

Primary research question: Are novel molecular tests for rapid detection of Mycoplasma and Gonorrhoea infections and antimicrobial resistance sensitive and specific in symptomatic patients attending a sexual health clinic? Secondary research question: Are novel molecular tests for detection of antimicrobial resistance in Mycoplasma and Gonorrhoea infections more accurate than standard laboratory culture techniques?

NCT ID: NCT05106803 Completed - Clinical trials for Surgical Site Infection

Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan

Start date: August 1, 2019
Phase:
Study type: Observational

The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

NCT ID: NCT04528043 Completed - Critically Ill Clinical Trials

Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care Unit

EB3REA
Start date: April 1, 2017
Phase:
Study type: Observational

There is a lack of data whether colonization and infection with Enterobacteriaceae of the third group (EB3) affect the outcomes for ICU patients. This study evaluated the effects of EB3 colonization and infection on ICU mortality, ICU length of stay (LOS) and broad-spectrum antibiotic exposure. We focused on the sub type Enterobacter regarding its a priori higher risk of resistance.

NCT ID: NCT04212403 Completed - Bladder Cancer Clinical Trials

Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)

Prophylaxis001
Start date: September 17, 2018
Phase: N/A
Study type: Interventional

To investigate the use of antibiotic prophylaxis in patients undergoing TURP and TURB. The investigators set up a prospective, randomized controlled trial in which (after exclusion of risk factors) patients will be randomized in receiving levofloxacin (Tavanic) orally or no antibiotics. The exclusion criteria for TURP are a pre-operative transurethral catheter or > 100 urinary white blood cells in the pre-operative urine sample. The exclusion criteria for TURB are a pre-op catheter or clinical signs of infection.

NCT ID: NCT04013737 Completed - Infection Clinical Trials

Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care

EPICIMPOC
Start date: February 28, 2017
Phase:
Study type: Observational

Antimicrobials (drugs that kill or stop the growth of microorganisms including bacteria, thereby treating infections) commonly used to treat patients with infections are becoming less effective over time as bacteria develop resistance to them. Antimicrobial usage itself can lead to development and spread of antimicrobial resistance. Antimicrobial resistance is now a major threat to patient safety. To conserve the effectiveness of antimicrobials the investigator need to develop ways to use them more sensibly healthcare professionals who diagnose and treat infections must be able to access antimicrobial guidelines and test results at the patient bedside. This needs to be provided rapidly and with support to make sure that the decisions on prescribing antimicrobials are the best that can be made.

NCT ID: NCT03866291 Completed - Clinical trials for Antibiotic Resistant Infection

ESBL in Patients Returning to Sweden With Traveller's Diarrhoea

Start date: February 1, 2017
Phase:
Study type: Observational

Patients with traveller's diarrhoea frequently harbour Extended Spectrum Betalactamase (ESBL)-producing Enterobacteriaceae (EPE) returning from EPE-endemic areas. This study investigates to what extent travellers returning to Sweden with traveller's diarrhoea carry ESBL in their stool. The isolates are examined further according to species, phenotype, antibiogram and whole genome sequencing.

NCT ID: NCT03860415 Completed - Clinical trials for Antibiotic Resistant Infection

Can Probiotic Vivomixx Eradicate Colonization With ESBL?

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Can probiotic Vivomixx eradicate Extended Spectrum BetaLactam (ESBL) colonization in adult patients?

NCT ID: NCT03848091 Completed - Clinical trials for Antibiotic Resistant Infection

Prosthesis Infection and One-step Exchange: Pretreatment by Targeted Antibiotic Therapy in At-risk Patients

Start date: April 1, 2016
Phase:
Study type: Observational

One-step exchange arthroplasty is more and more used in the treatment of chronic infections, especially in patients at risk anesthetic. This strategy is not recommended in patients infected with multidrug-resistant organisms or difficult to treat because of a risk of bacterial persistence on the new implant. Antibiotic pretreatment by a narrow-spectrum molecule and for which resistance acquisition is difficult might be of interest to try to reduce the inoculum and avoid contamination of the new implant.

NCT ID: NCT03721562 Completed - Clinical trials for Antibiotic Resistant Infection

Antibiotic Resistance in Global Pediatric Oncology Centers

Start date: February 26, 2019
Phase:
Study type: Observational

Antibiotic resistance is one of the major health threats facing global as well as domestic populations, however it is not well characterized in pediatric patients. Pediatric patients receiving cancer-directed therapy have several risk factors implicated in development of antibiotic resistance including multiple courses of antibiotics, repeated exposures to the hospital environment, indwelling devices and chemotherapy-related damage to mucosal barriers. The investigators propose to capitalize upon the unique position of St. Jude Global within the global pediatric oncology community by using its regional alliance network to describe the molecular epidemiology of antibiotic resistance in Gram-negative bacteria in this population. Primary Objectives 1. Describe the epidemiology and the phenotypic and previously determined molecular determinants of antimicrobial resistance in Gram-negative organisms isolated from pediatric diagnostic specimens in selected Central American and US sites with capacity to treat pediatric cancer 2. Utilize strain typing by whole genome sequencing to describe relatedness between organisms at participating sites